# A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Source: https://onco.cc/trials/nct06492616/  
OnCo record `nct06492616` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Elacestrant, Exemestane and Tamoxifen in advanced solid tumours, run by Stemline Therapeutics, Inc., now recruiting.

## Summary

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence is a phase 3 interventional study registered as NCT06492616 by Stemline Therapeutics, Inc., with 4220 participants planned, started 2024-09-27 and due to reach its primary completion in 2029-08. Interventions recorded: Elacestrant, Anastrozole, Letrozole, Exemestane and Tamoxifen.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06492616
- Phase: 3
- Setting: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study
- Sponsor: Stemline Therapeutics, Inc.
- Enrolled: 4220

## Sources

- ClinicalTrials.gov NCT06492616: https://clinicaltrials.gov/study/NCT06492616

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Elacestrant](https://onco.cc/drugs/elacestrant/), [Exemestane](https://onco.cc/drugs/exemestane/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- companies: [Menarini / Stemline](https://onco.cc/companies/menarini/)

---
JSON: https://onco.cc/api/v1/entities/nct06492616.json